Premenstrual dysphoric disorder medication

• US 20050250746A1
• Filed: 05/06/2004
• Published: 11/10/2005
• Est. Priority Date: 05/06/2004
• Status: Abandoned Application

• Current Assignee: Matthew Iammatteo
• Original Assignee: Matthew Iammatteo
• Inventors: Iammatteo, Matthew
• Application Number:
  US10/840,131
• Publication Number:
  US 20050250746A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A medication to treat the symptoms of premenstrual syndrome and similar conditions related to the periodic change in the physiological level of hormones in a woman'"'"'s body.

Claims

1. A product for treating premenstrual dysphoric disorder, comprising:

a. a hormone comprising estrogen and progesterone; and

b. a selective serotonin reuptake inhibitor;

c. said estrogen and said progesterone present in amounts which together are effective as a contraceptive; and

d. said selective serotonin reuptake inhibitor present in an amount effective to reduce emotional impairment related to premenstrual dysphoric disorder, when administered with said hormone.

2. The product of claim 1, wherein:

c. said estrogen and said progesterone are present in amounts which together are effective as a contraceptive during luteal phase; and

d. said selective serotonin reuptake inhibitor present in an amount effective to reduce emotional impairment related to premenstrual dysphoric disorder, when administered with said hormone during luteal phase.

3. The product of claim 2, formulated as an oral dosage form.

4. The product of claim 2, formulated as a transdermal skin patch.

5. The product of claim 1, formulated as an intra-vaginal ring.

6. The product of claim 1, formulated as an oral dosage form.

7. The product of claim 1, formulated as a transdermal skin patch.

8. The product of claim 1, formulated as an intra-vaginal ring.

9. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 1 to a premenstrual dysphoric disorder patient.

10. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 2 to a premenstrual dysphoric disorder patient.

11. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 3 to a premenstrual dysphoric disorder patient.

12. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 4 to a premenstrual dysphoric disorder patient.

13. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 5 to a premenstrual dysphoric disorder patient.

14. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 6 to a premenstrual dysphoric disorder patient.

15. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 7 to a premenstrual dysphoric disorder patient.

16. A method for treating premenstrual dysphoric disorder, the method comprising administering the product of claim 8 to a premenstrual dysphoric disorder patient.

17. A product for treating postmenopausal depression, comprising:

a. a hormone comprising estrogen; and

b. a selective serotonin reuptake inhibitor;

c. said estrogen present in hormone replacement therapy-effective amount; and

d. said selective serotonin reuptake inhibitor present in an amount effective to reduce depression in a postmenopausal patient, when administered with said hormone.

18. The product of claim 17, formulated as an oral dosage form.

19. The product of claim 17, formulated as a transdermal skin patch.

20. The product of claim 17, said hormone further comprising progesterone in a hormone replacement therapy-effective amount.

21. A method for treating postmenopausal depression, the method comprising administering the product of claim 17 to a postmenopausal patient.

22. A method for treating postmenopausal depression, the method comprising administering the product of claim 18 to a postmenopausal patient.

23. A method for treating postmenopausal depression, the method comprising administering the product of claim 19 to a postmenopausal patient.

24. A method for treating postmenopausal depression, the method comprising administering the product of claim 20 to a postmenopausal patient.